Adverse pregnancy outcomes (APOs) are associated with future development of CVD. The statement from the American Heart Association gives recommendations for strategies to reduce the long-term CVD risk in women with APOs.
Elevated levels of apoB and non-HDL-c better reflect residual risk for all-cause mortality and MI than LDL-c levels in patients treated with statins.
The ESC/EASD risk model was less accurate in prediction of 10-year CVD and all-cause mortality in patients with T2DM compared to SCORE and most notably to single assessment of NT-proBNP.
Subgroup analyses from DAPA-HF and EMPEROR-Reduced evaluated the effects of dapagliflozin and empagliflozin on CV and kidney outcomes according to baseline kidney function in patients with HFrEF.
Tirzepatide, a dual glucose-dependent insulinotropic peptide/GLP-1 receptor agonist (GIP/GLP-1RA), significantly improved glycemic control and reduced body weight in patients with T2DM.
A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.
This exploratory analysis from DAPA-HF showed that dapagliflozin, compared to placebo, reduced new-onset T2DM in patients with HFrEF without diabetes at baseline.
This study investigated the relative risk of more than 50 clinical risk factors and biomarkers with incident CHD in 4 age groups in women.
A risk score based on elevated levels of hs-cTnT, NT-proBNP, and hs-CRP, and presence of left ventricular hypertrophy can stratify incident HF risk in patients with dysglycemia without CVD.
5 Things a cardiologist needs to know about GLP-1 RA Prof. Deanfield discusses the changing paradigm for managing cardiometabolic risk in clinical practice by the emergence of diabetes. He states that GLP-1 receptor agonists will be an important component of treatment strategies.
Three speakers discuss several aspects of CV risk in diabetes: the role for primary care in reducing CV risk factors, the role of GLP-1RAs in reducing CV risk and recommendations in the newest ESC guidelines on diabetes and CVD.
This educational program consists of three presentations on residual CVD risk with a focus on triglycerides and triglyceride-rich lipoproteins.